Brieanne Mc Laughlin, Cpa
About Brieanne Mc Laughlin, Cpa
Brieanne McLaughlin is a CPA and currently serves as the Director of SEC Reporting and Technical Accounting at Organogenesis in Canton, Massachusetts. She has extensive experience in financial reporting and accounting, having held various positions at firms such as RSM US LLP, EY, and Boston Dynamics.
Work at Organogenesis
Brieanne Mc Laughlin serves as the Director of SEC Reporting and Technical Accounting at Organogenesis, a role she has held since 2024. Based in Canton, Massachusetts, she works in a hybrid capacity. In this position, she is responsible for overseeing the company's compliance with SEC regulations and managing technical accounting matters.
Previous Experience
Prior to her current role, Brieanne Mc Laughlin held several positions in the accounting and finance sector. She worked as the Director of Financial Reporting at Seres Therapeutics from 2022 to 2023. Before that, she was the Director of Technical Accounting and External Reporting at Boston Dynamics from 2021 to 2022. Her experience also includes roles at EY, where she served as a Senior Manager and Manager in Financial Accounting Advisory Services, and at RSM US LLP as an Assurance Manager.
Education and Expertise
Brieanne Mc Laughlin holds a Master of Science in Accounting and an MBA from Northeastern University, where she studied from 2004 to 2005. She also earned a Bachelor of Arts in Economics and Italian Studies from the University of Rochester, completing her studies there from 2000 to 2004. Her educational background provides a strong foundation for her expertise in accounting and financial reporting.
Career Progression
Brieanne Mc Laughlin's career in accounting began as an Assurance Associate at Caturano and Company from 2005 to 2007. She advanced to Assurance Senior Associate at the same firm until 2010. Following this, she joined RSM US LLP as an Assurance Manager for six years. After her tenure at RSM, she transitioned to EY, where she worked for a total of five years in various managerial roles before moving to Boston Dynamics and subsequently to Seres Therapeutics.